This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): R7204, PLX4032, RO5185426, RG7204, vemurafenib
Description: PLX4032 is a small molecule inhibitor of B-RafV600E kinase, which carries a mutation harbored by most malignant melanomas, a significant number of thyroid and colorectal cancers, and several other cancer types.
Revenue splits are BioMedTracker estimates.
Plexxikon & Roche
In October 2006, Plexxikon and Roche announced that the Companies have entered into an agreement to develop and commercialize PLX4032.
Under the terms of the agreement, Roche will pay Plexxikon $40 million as an upfront payment and a further $6 million in guaranteed research funding over the next two years. In addition, Plexxikon could potentially receive up to approximately $660 million over the term of the collaboration based on the successful completion of a series of development and commercial milestones for multiple indications and/or multiple compounds, as well as royalties on potential product sales.
Also under the collaboration, Roche and Plexxikon will jointly develop PLX4032 and follow on compounds targeting other BRAF kinase mutations. Roche will have a worldwide, exclusive license to develop and commercialize PLX4032, in addition to other anticancer compounds resulting...See full deal structure in Biomedtracker
Partners: Daiichi Sankyo Co., Ltd. Chugai Pharmaceutical Co., Ltd.
Additional information available to subscribers only: